23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Genetic polymorphisms in oxidative stress-related genes are associated with clinical outcome in patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitors.

      Read this article at

      ScienceOpenPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Many types of cancer have high antioxidant capacity that effectively scavenges reactive oxygen species and thus protect cancer cells against oxidative damage. The aim of this study was to examine the effect of 20 single nucleotide polymorphisms (SNPs) in 20 oxidative stress-related genes on clinical outcome in 219 patients with advanced non-small cell lung cancer (NSCLC) who were treated with EGFR tyrosine kinase inhibitors (TKIs). We assessed the associations of SNPs with prognosis in all patients as well as stratified by clinical characteristics. Three SNP (rs1695, rs2333227 and rs699512) were significantly associated with overall survival (OS). In a multivariate analysis, rs1695 AA and rs2333227 AG/GG genotypes were identified as independent prognostic factors for poor OS. Stratification analyses revealed that these 3 SNPs remained significantly associated with OS. Furthermore, there was a strong gene-dosage effect of these 3 SNPs on OS that patients with increasing number of unfavorable genotypes had significantly increased death risk. In conclusion, our findings provide the first evidence that genetic variants in oxidative stress-related genes may influence treatment outcome in advanced NSCLC patients receiving EGFR TKIs.

          Related collections

          Author and article information

          Journal
          Am J Cancer Res
          American journal of cancer research
          2156-6976
          2014
          : 4
          : 6
          Affiliations
          [1 ] Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University Shanghai, China.
          [2 ] Department of Surgical Oncology, Quanzhou First Hospital Quanzhou, Fujian, China.
          [3 ] Department of Surgical Oncology, Taizhou Central Hospital Taizhou, Zhejiang, China.
          [4 ] Department of Thoracic Surgery, Taizhou Hospital Taizhou, Zhejiang, China.
          [5 ] Shanghai Engineering Center for Molecular Medicine, National Engineering Center for Biochip at Shanghai Shanghai, China.
          [6 ] Department of Thoracic Surgery, Taizhou Central Hospital Taizhou, Zhejiang, China.
          Article
          4266725
          25520881
          fdb9345a-a301-4c80-851c-60b6214379a8
          History

          Tyrosine kinase inhibitor,biliverdin reductase A,glutathione S-transferases P1,lung cancer,myeloperoxidase,oxidative stress,single nucleotide polymorphism

          Comments

          Comment on this article